Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Depreciation and Depletion (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Depreciation and Depletion for 6 consecutive years, with $599000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation and Depletion fell 55.1% to $599000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.6 million, a 34.9% decrease, with the full-year FY2025 number at $3.6 million, down 34.9% from a year prior.
  • Depreciation and Depletion was $599000.0 for Q4 2025 at Relay Therapeutics, down from $748000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $1.4 million in Q1 2024 to a low of $599000.0 in Q4 2025.
  • A 5-year average of $1.1 million and a median of $1.1 million in 2021 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: soared 39.54% in 2023, then plummeted 55.1% in 2025.
  • Relay Therapeutics' Depreciation and Depletion stood at $1.0 million in 2021, then increased by 12.77% to $1.2 million in 2022, then grew by 17.92% to $1.4 million in 2023, then decreased by 2.98% to $1.3 million in 2024, then tumbled by 55.1% to $599000.0 in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Depreciation and Depletion are $599000.0 (Q4 2025), $748000.0 (Q3 2025), and $1.0 million (Q2 2025).